KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $184.5 million.

  • Supernus Pharmaceuticals' Accumulated Expenses rose 906.73% to $184.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.5 million, marking a year-over-year increase of 906.73%. This contributed to the annual value of $168.7 million for FY2024, which is 935.41% up from last year.
  • Supernus Pharmaceuticals' Accumulated Expenses amounted to $184.5 million in Q3 2025, which was up 906.73% from $180.9 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Accumulated Expenses peaked at $184.5 million during Q3 2025, and registered a low of $128.7 million during Q1 2021.
  • For the 5-year period, Supernus Pharmaceuticals' Accumulated Expenses averaged around $157.5 million, with its median value being $158.5 million (2022).
  • In the last 5 years, Supernus Pharmaceuticals' Accumulated Expenses skyrocketed by 2046.63% in 2021 and then crashed by 1603.53% in 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Accumulated Expenses (Quarter) stood at $132.7 million in 2021, then grew by 14.27% to $151.7 million in 2022, then increased by 1.72% to $154.3 million in 2023, then grew by 9.35% to $168.7 million in 2024, then grew by 9.34% to $184.5 million in 2025.
  • Its Accumulated Expenses was $184.5 million in Q3 2025, compared to $180.9 million in Q2 2025 and $170.1 million in Q1 2025.